Therapies for Inherited Retinal Dystrophies: What is Enough?

被引：2

作者：

Leroy, Bart P. ^{[1
,2
,3
]}

Daly, Avril ^{[4
]}

Heon, Elise ^{[5
]}

Sahel, Jose-Alain ^{[6
,7
,8
]}

Dollfus, Helene ^{[9
]}

机构：

[1] Ghent Univ Hosp, Dept Ophthalmol, Ghent, Belgium

[2] Univ Ghent, Dept Head & Skin, ERN EYE, Ghent, Belgium

[3] Childrenss Hosp Philadelphia, Div Ophthalmol, Philadelphia, PA USA

[4] Retina Int, Dublin, Ireland

[5] Univ Toronto, Hosp Sick Children, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada

[6] ERN EYE, CHNO Quinze Vingts, INSERM DGOS CIC 1423, Paris, France

[7] Sorbonne Univ, Inst Vis, INSERM, CNRS, Paris, France

[8] Univ Pittsburgh, Dept Ophthalmol, Sch Med, Pittsburgh, PA USA

[9] Univ Strasbourg, Hop Univ Strasbourg, Inst Genet Med Alsace IGMA, Ctr Reference Affect Rares Genet Ophtalmol CRMR CA, Strasbourg, France

来源：

DRUG DISCOVERY TODAY | 2024年 / 29卷 / 09期

关键词：

CANADA;

D O I：

10.1016/j.drudis.2024.104095

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页数：3

共 10 条

[1] Center for Drug Evaluation and Adaptive Design, 2020, Clinical Trials for Drugs and Biologics Guidance for Industry
[2] Novel mobility test to assess functional vision in patients with inherited retinal dystrophies
Chung, Daniel C.
McCague, Sarah
Yu, Zi-Fan
Thill, Satha
DiStefano-Pappas, Julie
Bennett, Jean
Cross, Dominique
Marshall, Kathleen
Wellman, Jennifer
High, Katherine A.
[J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 46 (03) : 247 - 259
[3] European Medical Agency, 2016, Guidance for companies considering the adaptive pathways approach
[4] European Medicines Agency, 2023, SINGLE ARM TRIALS PI
[5] The Impact of Inherited Retinal Diseases in the United States of America (US) and Canada from a Cost-of-Illness Perspective
Gong, Jennifer
Cheung, Simone
Fasso-Opie, Alivia
Galvin, Orla
Moniz, Larissa S.
Earle, Doug
Durham, Todd
Menzo, Jason
Li, Nan
Duffy, Stephanie
Dolgin, Jill
Shearman, Mark S.
Fiorani, Chiara
Banhazi, Judit
Daly, Avril
[J]. CLINICAL OPHTHALMOLOGY, 2021, 15 : 2855 - 2866
[6] Heon E, 2021, CAN J OPHTHALMOL, V56, pE34, DOI 10.1016/j.jcjo.2020.10.019
[7] Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial
Maclaren, Robert E.
Fischer, M. Dominik
Gow, James A.
Lam, Byron L.
Sankila, Eeva-Marja K.
Girach, Aniz
Panda, Sushil
Yoon, Dan
Zhao, Guolin
Pennesi, Mark E.
[J]. NATURE MEDICINE, 2023, 29 (10) : 2464 - +
[8] Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy Results of Phase 1 and 3 Trials
Maguire, Albert M.
Russell, Stephen
Wellman, Jennifer A.
Chung, Daniel C.
Yu, Zi-Fan
Tillman, Amy
Wittes, Janet
Pappas, Julie
Elci, Okan
Marshall, Kathleen A.
McCague, Sarah
Reichert, Hannah
Davis, Maria
Simonelli, Francesca
Leroy, Bart P.
Wright, J. Fraser
High, Katherine A.
Bennett, Jean
[J]. OPHTHALMOLOGY, 2019, 126 (09) : 1273 - 1285
[9] ProQR Therapeutics N.V, 2023, ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
[10] Depicting brighter possibilities for treating blindness
Sahel, Jose-Alain
Bennett, Jean
Roska, Botond
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (494)

← 1 →